Genitourinary Cancers | Specialty

Molecular Subtypes Correlate With Outcomes in RCC

January 16th 2018

Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.

Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney Cancer

January 16th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer

January 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses choosing a checkpoint inhibitor in bladder cancer.

Dr. Hammers on the Long-Term Benefits of the CheckMate-214 Study in RCC

January 11th 2018

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the long-term benefits of the CheckMate-214 study in patients with renal cell carcinoma (RCC).

Combinations Continue to Advance RCC Treatment

January 11th 2018

Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.

McDermott Shares Insight on Immunotherapy in RCC

January 10th 2018

David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.

Dr. Zhang on Toxicities of Treatments in RCC

January 9th 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the tolerability of agents used for the treatment of patients with renal cell carcinoma (RCC).

Dr. Graff Discusses the Treatment of Prostate Cancer

January 9th 2018

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC

January 9th 2018

The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

January 6th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the next steps following progression on immunotherapy for patients with bladder cancer.

Dr. McKay Discusses Advances in the Treatment of Metastatic RCC

January 5th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.

Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC

January 3rd 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Japan Approves Pembrolizumab for Urothelial Carcinoma

January 3rd 2018

The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

January 3rd 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Reflecting Back, Looking Forward in Urology Practice

December 30th 2017

Because of vertical integration, this has allowed us to maintain economic stability in the face of diminishing reimbursement for professional services.

Dr. Agarwal on the CheckMate-214 Trial for Kidney Cancer

December 29th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Dr. McDermott on Immunotherapy as a Standard of Care in RCC

December 28th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Treating Advanced Bladder Cancer in the Future

December 28th 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

December 28th 2017

Immunotherapy in Second-Line Advanced Bladder Cancer

December 28th 2017